Sarbajit Mukherjee: Trifluridine/ Tipiracil and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and GEJ Adenocarcinoma

Sarbajit Mukherjee, Chief of GI medical oncology at Miami Cancer Institute, posted on LinkedIn about recent paper he and his colleagues co-authored:

“Proud to announce that our clinical trial has been published!

This milestone represents six years of teamwork from its inception to its publication. It’s my first publication since joining Miami Cancer Institute. I’m grateful for the support from the National Comprehensive Cancer Network, Roswell Park Comprehensive Cancer Center colleagues, collaborators from the University of Oklahoma Health Sciences Center UChicago Medicine, and Natera.

This trial was especially personal as it was my first grant-funded study. Our team navigated challenging times during COVID-19 to achieve this.

A heartfelt thank you to the brave patients who participated in our study.”

Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: A Phase II Study

Authors: Sarbajit Mukherjee, Hassan Hatoum et al.

More posts featuring Sarbajit Mukherjee.